UOC
AXSM icon

UBS O'Connor’s Axsome Therapeutics AXSM Stock Holding History

UBS O'Connor’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,400
Closed -$668K – 298
2025
Q2 		$668K Buy
+6,400
New +$678K 0.02% 256
2024
Q4 		– Sell
-15,666
Closed -$1.41M – 442
2024
Q3 		$1.41M Buy
15,666
+548
+4% +$47.8K 0.03% 235
2024
Q2 		$1.22M Buy
15,118
+6,200
+70% +$459K 0.03% 270
2024
Q1 		$712K Sell
8,918
-3,004
-25% -$252K 0.02% 308
2023
Q4 		$949K Sell
11,922
-13,813
-54% -$923K 0.03% 276
2023
Q3 		$1.8M Hold
25,735
– – 0.03% 260
2023
Q2 		$1.85M Buy
25,735
+3,169
+14% +$234K 0.04% 313
2023
Q1 		$1.39M Buy
22,566
+12,075
+115% +$793K 0.03% 377
2022
Q4 		$809K Buy
10,491
+5,491
+110% +$328K 0.01% 586
2022
Q3 		$223K Sell
5,000
-23,026
-82% -$1.15M ﹤0.01% 843
2022
Q2 		$1.07M Buy
28,026
+6,126
+28% +$194K 0.01% 750
2022
Q1 		$906K Buy
+21,900
New +$679K 0.01% 711

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS O'Connor's AXSM Position: Q3 2025 in Review

UBS O'Connor sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 6,400 shares — an estimated $668K sold.

UBS O'Connor first reported a position in AXSM in Q1 2022 and held it in 12 quarters. The position peaked at $1.85M in Q2 2023. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • UBS O'Connor reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 6,400 Axsome Therapeutics shares in Q3 2025, an estimated $668K.
  • UBS O'Connor first reported a position in Axsome Therapeutics in Q1 2022 and held it in 12 quarters.
  • UBS O'Connor's Axsome Therapeutics position peaked at $1.85M in Q2 2023.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.